Charles Schwab Investment Management Inc. increased its stake in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 6.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 890,816 shares of the company's stock after acquiring an additional 56,399 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.69% of Surgery Partners worth $21,157,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of SGRY. PNC Financial Services Group Inc. increased its stake in shares of Surgery Partners by 86.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,169 shares of the company's stock valued at $28,000 after acquiring an additional 542 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Surgery Partners in the 1st quarter worth $65,000. State of Wyoming lifted its holdings in shares of Surgery Partners by 94.4% in the 4th quarter. State of Wyoming now owns 4,002 shares of the company's stock worth $85,000 after purchasing an additional 1,943 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Surgery Partners by 12.1% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,296 shares of the company's stock worth $91,000 after purchasing an additional 465 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Surgery Partners by 7,902.7% in the 1st quarter. GAMMA Investing LLC now owns 8,883 shares of the company's stock worth $211,000 after purchasing an additional 8,772 shares in the last quarter.
Analyst Upgrades and Downgrades
SGRY has been the topic of a number of recent research reports. Bank of America initiated coverage on Surgery Partners in a report on Monday, July 28th. They issued a "buy" rating and a $28.00 target price on the stock. Barclays cut their price objective on shares of Surgery Partners from $25.00 to $24.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 27th. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.00.
Read Our Latest Stock Analysis on SGRY
Insider Transactions at Surgery Partners
In related news, Director Teresa Deluca sold 20,018 shares of the business's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $22.74, for a total value of $455,209.32. Following the sale, the director directly owned 45,173 shares in the company, valued at approximately $1,027,234.02. The trade was a 30.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.70% of the company's stock.
Surgery Partners Stock Performance
Shares of SGRY traded down $0.60 during mid-day trading on Monday, hitting $23.04. The stock had a trading volume of 769,465 shares, compared to its average volume of 1,412,287. The firm has a market cap of $2.95 billion, a P/E ratio of -16.11 and a beta of 1.82. The business has a fifty day moving average price of $22.13 and a 200-day moving average price of $22.87. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.93 and a quick ratio of 1.78. Surgery Partners, Inc. has a 52 week low of $18.87 and a 52 week high of $33.97.
Surgery Partners (NASDAQ:SGRY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.01. Surgery Partners had a positive return on equity of 2.51% and a negative net margin of 5.57%.The business had revenue of $826.20 million for the quarter, compared to analysts' expectations of $816.96 million. During the same period in the previous year, the business posted $0.21 EPS. The firm's quarterly revenue was up 8.4% compared to the same quarter last year. On average, equities research analysts expect that Surgery Partners, Inc. will post 0.67 EPS for the current year.
About Surgery Partners
(
Free Report)
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Featured Articles
Before you consider Surgery Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.
While Surgery Partners currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access